Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05152914 · ClinicalTrials.gov registry record · Phase 1
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
A Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2, sponsored by David L Rogers, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05152914 is a Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2 that is active but no longer recruiting, run by David L Rogers, MD. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05152914, a Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2, is active but no longer recruiting, sponsored by David L Rogers, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
Conditions Studied
Interventions
- DRUG Cerliponase Alfa
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05152914
The ClinicalTrials.gov registry entry for NCT05152914 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David L Rogers, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuronal Ceroid Lipofuscinosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Cerliponase Alfa is the first listed.
NCT05152914 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05152914 about?
NCT05152914 is a clinical study titled "Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2". This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
What is the current status of trial NCT05152914?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-11-01. Estimated completion is 2027-11-01.
What conditions does trial NCT05152914 study?
This clinical trial studies the following conditions: Neuronal Ceroid Lipofuscinosis Type 2.
What interventions are being tested in trial NCT05152914?
The interventions under investigation include: Cerliponase Alfa (DRUG).
Who is sponsoring clinical trial NCT05152914?
This trial is sponsored by David L Rogers, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05152914 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.